Overview
Antibody-Drug Conjugates (ADCs) are an important therapeutic modality, combining the antigen specificity of monoclonal antibodies with the cytotoxic activity of small-molecule payloads. Throughout ADC development, researchers face challenges in target validation, conjugation strategy optimization, internalization analysis, and bioanalytical characterization.
ACROBiosystems provides integrated ADC research solutions spanning discovery through preclinical development, including target proteins, ADC conjugation kits, internalization detection tools, Fc receptor research tools, and ADC pharmacokinetic (PK) analysis solutions, including anti-payload antibodies and payload-specific ADC quantification ELISA kits. Our validated reagents support ADC research across key development stages.
Featured Articles
HotAug 25, 2026
Hot Antibody Internalization in ADC Development: What the Readout Can—and Cannot—Tell You
Antibody internalization mechanisms, key influencing factors, assay methods, and readout strategies for ADC candidate evaluation and development.
Read more
HotJul 31, 2026
Hot Reliable Antibody Internalization Assessment: Approaches and Considerations for Antibody Discovery and ADC Research
Antibody internalization is a fundamental step in the development of antibody therapeutics and antibody–drug conjugates (ADCs), providing valuable insights into intracellular antibody behavior following target binding. A range of experimental approaches has been developed to evaluate antibody internalization, each offering unique advantages and suited to different research applications.
Read more
HotJul 31, 2026
Hot Development and Optimization of a pH-Sensitive Fluorescence-Based Assay for Quantitative Antibody Internalization Analysis
Development and Optimization of a pH-Sensitive Fluorescence-Based Assay for Quantitative Antibody Internalization Analysis
Read moreExplore by Subtopics
.jpg)
Resources
Request PDF
Webinars
Get ACRO Insights in Your Inbox
Receive expert perspectives, research trends, and workflow guidance across emerging therapeutic fields.
Get ACRO Insights in Your Inbox
Frequently Asked Questions
What are the key quality attributes of antibody-drug conjugates?
Commonly evaluated quality attributes of ADCs include drug-to-antibody ratio (DAR), DAR distribution, purity, aggregation, free payload, linker integrity, plasma stability, and product consistency, among others. Together, these attributes support product characterization, quality control, and batch comparability throughout ADC development. Functional assays, including target binding, internalization, and cell-based potency testing, provide complementary information for evaluating the biological activity of ADC candidates.
How are targets selected for ADC development?
Target selection is one of the most important decisions in ADC development because it directly influences therapeutic specificity, safety, and clinical potential. An ideal ADC target is highly expressed on tumor cells with limited expression in normal tissues to minimize off-target toxicity. The target should also be accessible on the cell surface and capable of efficient ADC internalization, enabling intracellular release of the cytotoxic payload after antibody binding. Additional factors, such as target biology, expression heterogeneity, and disease relevance, are also considered during target evaluation.
What makes ADC development challenging?
ADC development is challenging because it requires coordinated optimization of multiple interdependent components, including the antibody, linker, and cytotoxic payload. Each component influences the efficacy, safety, stability, and pharmacokinetic properties of the final molecule. In addition, conjugation strategies can introduce product heterogeneity and variable drug-to-antibody ratios (DAR), increasing the complexity of bioanalytical characterization, quality control, and manufacturing consistency throughout the development process.
Explore More Topics
Cell and Gene Therapy
CMC Manufacturing & QC
Bispecific Antibodies
Disease Areas
Vaccines
